NxStage(R) Reports Significant Interim FREEDOM Stu...(Medical Inc. (Nasdaq: Forward-Looking S...),Health

Date:10/27/2009

Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to: expected growth in home daily hemodialysis and the anticipated impact and results of the FREEDOM study and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Kristen K. Sheppard, Esq.
    VP, Investor Relations
    ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.

'/>"/>

SOURCE NxStage Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. NxStage(R) to Report Third Quarter 2009 Financial Results
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
4. Hospira Reports Third-Quarter 2009 Results
5. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
6. Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance
7. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
8. Amylin Pharmaceuticals Reports Third Quarter Financial Results
9. Escalon(R) Reports Fourth Quarter and Fiscal 2009 Results
10. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
11. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results